Hotbed/Location
Filter News
Found 479,851 articles
-
Purus Labs Recalls MyoWhey due to Undeclared Allergens
9/21/2018
PURUS LABS ISSUES ALLERGY ALERT ON UNDECLARED MILK AND SOY IN MYOWHEY
-
Huntsman Cancer Foundation Announces Major Gifts to Support Hospital Expansion Plans
9/21/2018
Today Huntsman Cancer Foundation (HCF) announced that several individuals and business organizations have committed a total of $40 million to support a proposed major building expansion of Huntsman Cancer Institute (HCI) at the University of Utah (U of U).
-
Innovent Presents Clinical Data of Anti-PD-1 Antibody Sintilimab in Patients with Advanced Malignant Neuroendocrine Tumors at Annual Meeting of the Chinese Society of Clinical Oncology
9/21/2018
Innovent Biologics, Inc. (Innovent), a world-class China-based biopharmaceutical company that develops and commercializes high quality drugs, today presented clinical trial data from a phase Ib clinical trial (NCT02937116) that treated patients with neuroendocrine tumors
-
Acacia Network Releases Statement Reflecting On Hurricane María
9/21/2018
Acacia Network today issued the following statement reflecting on Hurricane María
-
Canon Medical System Corporation partners with ACT Genomics for Precision Cancer Medicine Service in Japan
9/21/2018
Canon Medical System Corporation completed the acquisition of the majority shares of ACTmed
-
Innovent Presents Clinical Data of Anti-PD-1 Antibody Sintilimab in Patients with Previously Treated Non-Small Cell Lung Cancer at Annual Meeting of the Chinese Society of Clinical Oncology
9/21/2018
Innovent Biologics, Inc. today presented clinical research data on cohort C at the 2018 Annual Meeting of Chinese Society of Clinical Oncology (CSCO).
-
Exelixis’ Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma
9/21/2018
In the phase 3 pivotal CELESTIAL trial, CABOMETYX demonstrated a statistically significant and clinically meaningful overall survival benefit
-
Ipsen Receives Positive CHMP Opinion for Cabometyx® (Cabozantinib) for the Second-line Treatment of Patients with Hepatocellular Carcinoma (HCC)
9/21/2018
Ipsen announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), provided a positive opinion for Cabometyx® (cabozantinib) as a monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults
-
Johnson & Johnson Vision Showcases Latest Clinical Data and Eye Care Solutions at the ESCRS 2018 Annual Meeting
9/21/2018
Latest clinical data builds on the wealth of evidence supporting the safety, efficacy and overall benefits of TECNIS Symfony® IOLs for cataract patients
-
TVARDI THERAPEUTICS, INC. SECURES $9 MILLION IN SERIES A FINANCING ROUND
9/21/2018
Tvardi Therapeutics Inc. (“Tvardi”), a clinical-stage private biopharmaceutical company focused on the development of STAT3 inhibitors, announced today the completion of a $9 million Series A financing round.
-
Molecular Templates and Takeda to Take on Multiple Myeloma in Deal Worth up to $632 Million
9/20/2018
Shares of Molecular Templates are up more than 52 percent in premarket trading after the company announced it has struck a deal with pharma giant Takeda Pharmaceuticals. -
Shares of OncoMed Pharmaceuticals are falling this morning after the company announced that Celgene has walked away from a deal to license the company’s bispecific antibody navicixizumab.
-
Amicus Therapeutics, headquartered in Cranbury, New Jersey, inked a definitive agreement for 10 gene therapy programs licensed from Nationwide Children’s Hospital through the acquisition of Celenex.
-
The two biggest areas for biotech startups in the U.S. are Cambridge in Boston and the San Francisco Bay Area. They’re also the locations of astonishingly expensive real estate. But they’re where biotechs seem to want to be because they’re close to talent, academic research institutions, and the ...
-
In 2015, Priscilla Chan, a physician, and her husband, Facebook founder and CEO Mark Zuckerberg, created the Chan Zuckerberg Initiative (CZI). CZI’s stated goal was resoundingly ambitious.
-
China’s Hillhouse Capital Group, an equity investment firm, has a new fund, Hillhouse Fund IV, with $10.6 billion ready to invest.
-
LineaRx, a subsidiary of Applied DNA Sciences, has entered into a Joint Development Agreement with Takis SRL and Evvivax SLR. They will focus on developing anti-cancer vaccines.
-
Ilan Danieli, chief executive officer and co-founder of Precipio, a company with a liquid biopsy technology, took time to talk to BioSpace about the company and the economics of liquid biopsies.
-
Mazars USA Announces New Healthcare Consulting Group Leader Amidst Ongoing National Growth
9/20/2018
Mazars USA LLP today announced Gil Enos, Principal, will be the new Healthcare Consulting Group Leader.
-
Celltrion Signs 'Incubation' Agreement with Emory University for Development of New Drugs for Atherosclerosis
9/20/2018
Research on new mechanisms to prevent ischemic heart disease and stroke, the leading causes of death in the world